CClinicalTrials.gg
CompletedNCT03143634MPMHUpdated Sep 29, 2020

The Modular Protocol for Mental Health (MPMH)

A Phase 1/2 interventional study of The Modular Protocol for Mental Health and Treatment-as-usual in Major Depressive Disorder, Generalized Anxiety Disorder and Posttraumatic Stress Disorder, sponsored by Medical Research Council Cognition and Brain Sciences Unit. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-09-29.

Sponsored by Medical Research Council Cognition and Brain Sciences Unit · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Currently, our best psychological treatments for anxiety and mood disorders only focus on individual diagnoses. So, there are separate treatments for Panic Disorder, or Depressive Disorder, or Social Anxiety, etc. These 'diagnosis-specific' treatments work well for people whose problems fit neatly into a single diagnosis. However, they work far less well for people with complex problems involving multiple diagnoses, and 50% of patients fail to respond well to these existing treatments.

The purpose of this study is to test a new psychological treatment for anxiety and mood problems (the Modular Protocol for Mental Health [MPMH]). Instead of focusing on any single diagnosis, MPMH combines the best treatment techniques into 10 modules to target problems common across all of the different mood and anxiety diagnoses (e.g., intense emotions, negative thinking, upsetting memories, distressing habits). MPMH should therefore be a better treatment for the large numbers of individuals whose problems do not fit neatly into a single diagnosis and for whom any treatments targeting a single diagnosis would leave significant difficulties unaddressed.

02

Conditions studied

  • Major Depressive Disorder
  • Generalized Anxiety Disorder
  • Posttraumatic Stress Disorder
  • Social Anxiety Disorder
  • Panic Disorder
  • Agoraphobia
  • Obsessive-Compulsive Disorder
  • Illness Anxiety Disorder
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with a primary diagnosis of a unipolar mood, anxiety, stress or obsessive-compulsive disorder with at least one additional comorbid diagnosis according to the DSM-5. The criteria for diagnosis will be based on the Structured Clinical Interview for the DSM (SCID) which assesses disorders according to DSM-5 diagnostic criteria.
  • To be eligible participants will also need to score >10 on either the Patient Health Questionnaire (PHQ-9) or Generalised Anxiety Disorder -7 item scale, GAD-7 (see Study Measures above).

Exclusion criteria

Exclusion Criteria:

  • Current/past psychosis or bipolar disorder
  • Current full diagnosis of substance use disorder
  • Organic brain damage
  • Complex trauma history or recurrent self-injury requiring specialist services (as deemed by the NHS Clinical Care team)
  • Current suicidality that warrants immediate clinical attention and constitutes a current risk of harm to the individual.
04

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    The Modular Protocol for Mental Health

    The Modular Protocol for Mental Health (Psychological Therapy) will last up to 18 regular weekly face-to-face sessions. Treatment follows a standard structured treatment session as per Cognitive Behavioural Therapy. The MPMH Treatment Manual was written by clinical psychologists. The selection and ordering of the modules for treatment will be delivered and determined by the Trial Clinical Psychologist in collaboration with the service-user. The treatment modules include: M1. Getting Acquainted M2. Understanding Emotions M3. Managing and Tolerating Emotions M4. Behavioural activation M5. Tackling Avoidance M6. Tackling Unhelpful Thoughts M7. Tackling Unhelpful Habits M8. Overcoming Repetitive Thinking M9. Managing Upsetting Memories and Images M10. Relapse Prevention and Future Orientation

    Behavioral: The Modular Protocol for Mental Health

  • Placebo comparator
    Treatment-as-usual

    For Treatment-as-usual (Psychological Therapy), clinicians will be asked to provide whatever treatment they deem appropriate, including psychological services, medication and referral to other services. TAU will be delivered by high-intensity therapists or clinical psychologists.

    Behavioral: Treatment-as-usual

Interventions

  • BehavioralThe Modular Protocol for Mental Health

    This intervention is based on evidence-based cognitive-behavioural approaches to psychological disorders and offers a flexible approach to treatment delivery that targets the maladaptive processes common to mood and anxiety disorders.

  • BehavioralTreatment-as-usual

    This intervention will consist of psychological therapies delivered by high-intensity therapists or clinical psychologists.

05

What researchers measure

Primary outcomes

  1. Change in Depression symptoms

    Patient Health Questionnaire - 9-item version (PHQ-9; Kroenke \& Spitzer, 2002)

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  2. Change in Anxiety symptoms

    General Anxiety Disorder Questionnaire - 7-item version (GAD-7; Spitzer, Kroenke, Williams, \& Lowe, 2006)

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  3. Change in Level of disability and functional impairment

    Work and Social Adjustment Scale (WSAS; Mundt, J.C. et al., 2002)

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

Secondary outcomes

  1. Change in symptoms of social phobia, agoraphobia and specific phobia

    IAPT Phobia Scales (Department of Health/IAPT, 2011). This measure will only be completed by participants with symptoms of social phobia, agoraphobia or specific phobia.

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  2. Change in symptoms of social anxiety

    The Social Phobia Inventory (SPIN; Connor, Davidson, Churchill, Sherwood, Foa, \& Weisler, 2000). This measure will only be completed by participants with symptoms of social anxiety.

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  3. Change in symptoms of generalised anxiety

    The Penn State Worry Questionnaire (PSWQ; Meyer, Miller, Metzger, \& Borkovec, 1990). This measure will only be completed by participants with symptoms of generalised anxiety disorder.

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  4. Change in symptoms of obsessive-compulsive disorder

    The Obsessive-Compulsive Inventory (OCI; Foa, Kozak, Salkovskis, Coles, \& Amir, 1998). This measure will only be completed by participants with symptoms of obsessive-compulsive disorder.

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  5. Change in symptoms of post-traumatic stress disorder

    The Revised Impact of Event Scale (IES-R; Weiss, 2007). This measure will only be completed by participants with symptoms of PTSD.

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  6. Change in symptoms of agoraphobia

    The Agoraphobia-Mobility Inventory (MI; Chambless, Caputo, Jasin, Gracely, \& Williams, 1985). This measure will only be completed by participants with symptoms of agoraphobia.

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  7. Change in symptoms of specific phobias

    The Fear Questionnaire (FQ; Marks \& Mathews, 1979). This measure will only be completed by participants with symptoms of specific phobia.

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  8. Change in symptoms of panic disorder

    The Panic Disorder Severity Scale - self report version (PDSS-SR; Shear, Brown, Barlow, Money, Sholomskas, Woods, Gorman, \& Papp, 1997). This measure will only be completed by participants with symptoms of panic disorder.

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  9. Change in symptoms of illness anxiety

    The Health Anxiety Inventory - short version (SHAI; Salkovskis, Rimes, Warwick, \& Clark, 2002). This measure will only be completed by participants with symptoms of illness anxiety.

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  10. Change in level of disability and functional impairment

    Sheehan Disability Scale (SDS; Sheehan, 1983)

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  11. Change in expectancy about treatment outcome, as well as the credibility of the treatment

    The Treatment Credibility / Expectancy Questionnaire (CEQ; Devilly \& Borkovec, 2000)

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  12. Change in ability to contextualize negative events within a wider frame of reference

    Cognitive Emotion Regulation Questionnaire (CERQ; Garnefski, Kraaij \& Spinhoven, 2000)

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  13. Change in disengagement from and acceptance of troublesome mental content, rumination

    Experiences Questionnaire (EQ; Fresco et al., 2007)

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  14. Intensity with which participants experience 36 different emotions on a typical day

    Differential Emotions Scale (DES; Izard, 1993)

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  15. Change in personality functioning on four subscales: Identity, Self-Direction, Empathy, and Intimacy

    Levels of Personality Functioning Scale (LPFS; Morey et al., 2017)

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  16. Change in use of NHS services, other mental health services or activities, help at home, and time off work/lost income

    Healthlines Resource Use Questionnaire (Salisbury, O'Cathain, Edwards, Thomas, Gaunt, Hollinghurst, et al., 2016)

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

  17. Change in quality of life assessment of health and wellbeing, daily functioning, and general life satisfaction across multiple domains

    World Health Organisation (WHO) Quality of Life Inventory (WHOQOL; World Health Organisation, 1998)

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session, three-months following final treatment session

Other outcomes

  1. Change in measure of memory specificity

    Autobiographical Memory Test (Williams \& Broadbent, 1986).

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session

  2. Change in cognitive flexibility for emotional information

    Affective Card Sorting Task (Barcelo, 2003; Deveney \& Deldin, 2006)

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session

  3. Change in immediate recall and working memory for neutral information

    Digit Span Task (Wechsler, 2008)

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session

  4. Change in brief measure of premorbid intelligence

    National Adult Reading Test (Nelson \& Wilson, 1991)

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session

  5. Change in emotional structure (awareness and differentiation)

    Levels of Emotional Awareness Scale (Lane et al., 1990)

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session

  6. Change in potential neurobiomarkers that may account for risk of disorders and/or predict treatment response (optional component of participation)

    Functional connectivity during resting state MRI

    Time frame: Baseline (within two weeks of first treatment session), within one week of the final treatment session

  7. Change in levels of rumination

    Ruminative Responses Scale of the Response Styles Questionnaire (RRS; Treynor, Gonzalez, Nolen-Hoeksema, 2003)

    Time frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)

  8. Change in ability to tolerate distress

    Distress Tolerance Scale (DTS; Simons \& Gaher, 2005)

    Time frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)

  9. Change in ability to label, perceive, and regulate emotions

    Difficulties with Emotion Regulation Scale (DERS; Gratz \& Roemer, 2004)

    Time frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)

  10. Change in negative beliefs, thoughts and assumptions

    Dysfunctional Attitudes Scale (DAS; Weissman, 1979)

    Time frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)

  11. Change in mindful awareness

    Kentucky Inventory of Mindfulness Skills (KIMS; Baer, Smith, \& Allen, 2004)

    Time frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)

  12. Change in fear of physical anxiety sensations

    Anxiety Sensitivity Index (ASI; Reiss, Peterson, Gursky, \& McNally 1986)

    Time frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)

  13. Change in trauma-related beliefs and maladaptive appraisals of intrusive symptoms

    Posttraumatic cognitions inventory - short version (PTCI; Foa, Ehlers, Clark, Tolin, Orsillo, 1999)

    Time frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)

  14. Change in implementation of cognitive therapy skills

    Skills of Cognitive Therapy (SoCT; Jarrett, 2010)

    Time frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)

  15. Change in avoidance of internal experiences including thoughts, feelings, physical sensations.

    The Multidimensional Experiential Avoidance Questionnaire (Gamez, Chmielewski, Kotov, Ruggero, \& Watson, 2011)

    Time frame: Within one-week pre-delivery of relevant treatment module; within one-week post-delivery of relevant treatment module (varied time-frame)

06

Study locations

1 site
  • MRC Cognition and Brain Sciences Unit
    Cambridge, CB2 7EF, United Kingdom
07

References and documents

Publications

  • First MB, Williams JBW, Karg RS, Spitzer RL: Structured Clinical Interview for DSM-5-Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV). Arlington, VA, American Psychiatric Association, 2015
  • Newby JM, McKinnon A, Kuyken W, Gilbody S, Dalgleish T. Systematic review and meta-analysis of transdiagnostic psychological treatments for anxiety and depressive disorders in adulthood. Clin Psychol Rev. 2015 Aug;40:91-110. doi: 10.1016/j.cpr.2015.06.002. Epub 2015 Jun 6. PubMed 26094079 ↗
  • Kroenke, K.; Spitzer, R.L.The PHQ-9: A new depression diagnostic and severity measure. Psychiatric Annals, Vol 32(9), Sep 2002, 509-515. http://dx.doi.org/10.3928/0048-5713-20020901-06
  • Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006 May 22;166(10):1092-7. doi: 10.1001/archinte.166.10.1092. PubMed 16717171 ↗
  • Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002 May;180:461-4. doi: 10.1192/bjp.180.5.461. PubMed 11983645 ↗
  • IAPT/Department of Health, The IAPT data handbook version 2.0.1. 2011: Published to Department of Health Website, in electronic PDF format only
  • Connor KM, Davidson JR, Churchill LE, Sherwood A, Foa E, Weisler RH. Psychometric properties of the Social Phobia Inventory (SPIN). New self-rating scale. Br J Psychiatry. 2000 Apr;176:379-86. doi: 10.1192/bjp.176.4.379. PubMed 10827888 ↗
  • Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 1990;28(6):487-95. doi: 10.1016/0005-7967(90)90135-6. PubMed 2076086 ↗
  • Foa, E.B., Kozak, M.J., Salkovskis, P.M., Coles, M.E., and Amir, N. (1998). The validation of a new obsessive-compulsive disorder scale: The Obsessive-Compulsive Inventory. Psychological Assessment, 10(3), 206-214.
  • Weiss, D.S., The Impact of Event Scale: Revised, in Cross-cultural assessment of psychological trauma and PTSD, J.P. Wilson and C.S. Tang, Editors. 2007, Springer: New York. p. 219-238.
  • Chambless DL, Caputo GC, Jasin SE, Gracely EJ, Williams C. The Mobility Inventory for Agoraphobia. Behav Res Ther. 1985;23(1):35-44. doi: 10.1016/0005-7967(85)90140-8. No abstract available. PubMed 3985915 ↗
  • Marks IM, Mathews AM. Brief standard self-rating for phobic patients. Behav Res Ther. 1979;17(3):263-7. doi: 10.1016/0005-7967(79)90041-x. No abstract available. PubMed 526242 ↗
  • Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, Gorman JM, Papp LA. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997 Nov;154(11):1571-5. doi: 10.1176/ajp.154.11.1571. PubMed 9356566 ↗
  • Salkovskis PM, Rimes KA, Warwick HM, Clark DM. The Health Anxiety Inventory: development and validation of scales for the measurement of health anxiety and hypochondriasis. Psychol Med. 2002 Jul;32(5):843-53. doi: 10.1017/s0033291702005822. PubMed 12171378 ↗
  • Sheehan, D.V., The Anxiety Disease. 1983, New York: Charles Scribner and Sons.
  • Devilly GJ, Borkovec TD. Psychometric properties of the credibility/expectancy questionnaire. J Behav Ther Exp Psychiatry. 2000 Jun;31(2):73-86. doi: 10.1016/s0005-7916(00)00012-4. PubMed 11132119 ↗
  • Garnefski N, Rieffe C, Jellesma F, Terwogt MM, Kraaij V. Cognitive emotion regulation strategies and emotional problems in 9 - 11-year-old children: the development of an instrument. Eur Child Adolesc Psychiatry. 2007 Feb;16(1):1-9. doi: 10.1007/s00787-006-0562-3. Epub 2006 Jun 21. PubMed 16791542 ↗
  • Fresco DM, Moore MT, van Dulmen MH, Segal ZV, Ma SH, Teasdale JD, Williams JM. Initial psychometric properties of the experiences questionnaire: validation of a self-report measure of decentering. Behav Ther. 2007 Sep;38(3):234-46. doi: 10.1016/j.beth.2006.08.003. Epub 2007 Apr 24. PubMed 17697849 ↗
  • Izard CE, Libero DZ, Putnam P, Haynes OM. Stability of emotion experiences and their relations to traits of personality. J Pers Soc Psychol. 1993 May;64(5):847-60. doi: 10.1037//0022-3514.64.5.847. PubMed 8505713 ↗
  • Morey LC. Development and initial evaluation of a self-report form of the DSM-5 Level of Personality Functioning Scale. Psychol Assess. 2017 Oct;29(10):1302-1308. doi: 10.1037/pas0000450. Epub 2017 Feb 27. PubMed 28240933 ↗
  • Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med. 1998 May;28(3):551-8. doi: 10.1017/s0033291798006667. PubMed 9626712 ↗
  • Salisbury C, O'Cathain A, Edwards L, Thomas C, Gaunt D, Hollinghurst S, Nicholl J, Large S, Yardley L, Lewis G, Foster A, Garner K, Horspool K, Man MS, Rogers A, Pope C, Dixon P, Montgomery AA. Effectiveness of an integrated telehealth service for patients with depression: a pragmatic randomised controlled trial of a complex intervention. Lancet Psychiatry. 2016 Jun;3(6):515-25. doi: 10.1016/S2215-0366(16)00083-3. Epub 2016 Apr 27. PubMed 27132075 ↗
  • Treynor, W., R. Gonzalez, and S. Nolen-Hoeksema, Rumination Reconsidered: A Psychometric Analysis. Cognitive Therapy and Research 2003. 27(3): p. 247-259.
  • Simons, J.S. and R.M. Gaher, The Distress Tolerance Scale: Development and Validation of a Self-Report Measure. Motivation and Emotion, 2005. 29(2): p. 83-102.
  • Gratz, K.L. & Roemer, L. Journal of Psychopathology and Behavioral Assessment (2004) 26: 41. doi:10.1023/B:JOBA.0000007455.08539.94
  • Weissman, A.N., The Dysfunctional Attitude Scale: A Validation Study. 1979, University of Pennsylvania.
  • Baer RA, Smith GT, Allen KB. Assessment of mindfulness by self-report: the Kentucky inventory of mindfulness skills. Assessment. 2004 Sep;11(3):191-206. doi: 10.1177/1073191104268029. PubMed 15358875 ↗
  • Reiss S, Peterson RA, Gursky DM, McNally RJ. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behav Res Ther. 1986;24(1):1-8. doi: 10.1016/0005-7967(86)90143-9. No abstract available. PubMed 3947307 ↗
  • Foa, E.B., Ehlers, A., Clark, D.M., Tolin, D.F., Orsillo, S.M., The Posttraumatic Cognitions Inventory (PTCI): Development and validation. Psychological Assessment, 1999. 11(3): p. 303-314.
  • Jarrett RB, Vittengl JR, Clark LA, Thase ME. Skills of Cognitive Therapy (SoCT): a new measure of patients' comprehension and use. Psychol Assess. 2011 Sep;23(3):578-86. doi: 10.1037/a0022485. PubMed 21319902 ↗
  • Gamez W, Chmielewski M, Kotov R, Ruggero C, Watson D. Development of a measure of experiential avoidance: the Multidimensional Experiential Avoidance Questionnaire. Psychol Assess. 2011 Sep;23(3):692-713. doi: 10.1037/a0023242. PubMed 21534697 ↗
  • Williams JM, Broadbent K. Autobiographical memory in suicide attempters. J Abnorm Psychol. 1986 May;95(2):144-9. doi: 10.1037//0021-843x.95.2.144. No abstract available. PubMed 3711438 ↗
  • Deveney CM, Deldin PJ. A preliminary investigation of cognitive flexibility for emotional information in major depressive disorder and non-psychiatric controls. Emotion. 2006 Aug;6(3):429-437. doi: 10.1037/1528-3542.6.3.429. PubMed 16938084 ↗
  • Barcelo F. The Madrid card sorting test (MCST): a task switching paradigm to study executive attention with event-related potentials. Brain Res Brain Res Protoc. 2003 Mar;11(1):27-37. doi: 10.1016/s1385-299x(03)00013-8. PubMed 12697260 ↗
  • Wechsler, D. (2008). Wechsler Adult Intelligence Scale-Fourth Edition. San Antonio, TX: Pearson.
  • Nelson HE, Wilson J (1991) National Adult Reading Test (NART), NFER-Nelson, Windsor, UK.
  • Lane RD, Quinlan DM, Schwartz GE, Walker PA, Zeitlin SB. The Levels of Emotional Awareness Scale: a cognitive-developmental measure of emotion. J Pers Assess. 1990 Fall;55(1-2):124-34. doi: 10.1080/00223891.1990.9674052. PubMed 2231235 ↗
  • Black M, Hitchcock C, Bevan A, O Leary C, Clarke J, Elliott R, Watson P, LaFortune L, Rae S, Gilbody S, Kuyken W, Johnston D, Newby JM, Dalgleish T. The HARMONIC trial: study protocol for a randomised controlled feasibility trial of Shaping Healthy Minds-a modular transdiagnostic intervention for mood, stressor-related and anxiety disorders in adults. BMJ Open. 2018 Aug 5;8(8):e024546. doi: 10.1136/bmjopen-2018-024546. PubMed 30082367 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03143634
Lead sponsor
Medical Research Council Cognition and Brain Sciences Unit
Collaborators
Cambridgeshire and Peterborough NHS Foundation Trust
Responsible party
Sponsor
First posted
May 8, 2017
Start date
Jul 18, 2017
Primary completion
Jul 31, 2020
Completion
Jul 31, 2020
Last update
Sep 29, 2020

Study contacts

Tim Dalgleish, PhD
principal investigator · Medical Research Council Cognition and Brain Sciences Unit

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion